LDS/Medical Tests/Hydromorphone, Urine

Hydromorphone, Urine

Hydromorphone is a semisynthetic opioid agonist. Hydromorphone does not require metabolic activation, and is 7-10 times more potent than morphine. Hydromorphone is also a metabolite of hydrocodone. It is rapidly metabolized after oral administration to pharmacologically active 6alpha and 6beta-hydroxy derivatives, and glucuronide conjugates. The half-life of hydromorphone is 3-9 hours for the immediate release forms, and 12-22 hours for the extended release form. Typical routes of administration are oral, intramuscular, intravenous, subcutaneous, or rectal.

Approximately 36% of an oral dose will appear in the urine within 24 hours of administration, primarily as glucuronidated conjugate.   

Common side effects: respiratory depression, sedation, nausea, vomiting, dizziness, miosis, constipation, urinary retention. Hydromorphone can also contribute to the following effects: euphoria, mental clouding, amnesia, hostility, irritability, pruritis, and vivid or disturbing dreams. Can be addictive. Overdose effects include respiratory collapse, seizure, coma, and possible death.  

Hydromorphone can be detected in urine by a variety of analytical methods (see below); both qualitative and quantitative tests are available.

  • Adherence monitoring
  • Drug abuse evaluation
  • Toxicity/Overdose assessment
A positive result indicates only the presence of Hydromorphone and does not necessarily correlate with the extent of physiological and psychological effects, nor does it predict the dose that was taken or administered. Any result that is inconsistent with clinical expectations should be confirmed or quantitated by a second method.

Therapeutic Level10: 100 ng/mL
Toxic level: >200 ng/mL

Note: therapeutic ranges and toxic thresholds are best evaluated from blood samples. Quantitative results obtained with blood samples collected at specific times after drug administration are preferred for pharmacokinetic analyses.

Cut-Off Ranges
Cut-off values are used to determine the positivity of the urine specimen being analyzed. Cut-off values can vary based on the particular method of analysis that is used for detection, or laboratory, or whether the test is a qualitative method or a quantitative method. Detection will be improved with low cutoff concentrations. The testing laboratory cut-off range is listed on the patient report.

Many, including Liquid Chromatography/Mass Spectroscopy (LC/MS, LC-MS/MS), Gas Chromatography/Mass Spectroscopy (GC/MS), or Thin Layer Chromatography (TLC). Immunoassays designed to specifically detect hydromorphone are not available. Immunoassays designed to detect opiates are generally not sensitive or specific to hydromorphone. Targeted assays can detect hydromorphone but may not detect metabolites. Many laboratories include a pre-analytical hydrolysis reaction to liberate the glucuronide conjugates, which may improve detection.

Fresh urine specimen (random) collected in either a clean glass or plastic container. An acceptable urine specimen submitted for testing should be in the pH range of 3-11. Creatinine or specific gravity results will identify dilute specimens. Adulteration of the urine specimen can result in erroneous results.

Stability

  • Ambient: 5 days
  • Refrigerated: 7 days
  • Frozen: 30 days
Pharmacogenetic testing such as genotyping for *CYP3A4, CYP3A5, CYP2D6, CYP2C9, CYP2C19,* and *OPRM1* variants could guide drug and dose selection. Patients with poor or rapid metabolizer phenotypes for *CYP2D6* should not receive codeine because of the inherent risk of therapeutic failure or toxicity, respectively. Supportive testing such as a liver profile, kidney profile, comprehensive metabolic panel, CBC, and testing for concomitant drugs may be appropriate.
1-3 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
  • Baselt RC (ed). Disposition of toxic drugs and chemicals in man, 9th ed. Forster City, CA: Biomedical Publications; 2011.
  • Brunton LL, Chabner B, Knollman B (eds). Goodman and Gilmans’ the pharmacological basis of therapeutics, 12th ed. New York: McGraw-Hill; 2010.
  • Katzung BG, Masters S, Trevor AK (eds). Basic and clinical pharmacology, 12th ed. New York: McGraw-Hill; 2011.